
About Ortin Laboratories
Ortin Laboratories is a publicly listed company based in Hyderabad (India) founded in 1986. Entertainment talent is connected to projects through a digital platform. It operates on a Reseller / Distribution and B2B2C model. Its chief executive, as recorded, is Murali Krishna Murthy Sanka. Its Indian entity Ortin Global Limited reported revenue of βΉ41 Lakh. Ortin Laboratories offers products and services including Formulations, API, Intermediates, and Bio-technology. Its focus areas include Pharmaceuticals and Drug Manufacturing.
Company details
Ortin Laboratories Limited is involved in the development and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and chemical intermediates. The company is also active in biotechnology solutions and merchant export trading. Operations are focused on the healthcare sector, providing products for medical and research applications. Additionally, export and import business opportunities are pursued to expand global presence. The company is based in Hyderabad, India, and serves various clients worldwide.
- Headquarters Hyderabad, India
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website ortinlabsindia.com
- Legal Name Ortin Global Ltd
- Market Cap₹10.51 Cr
ORTINGLOBE · NSE
- Share Price₹12.50
-3.33% today
- Revenue₹0.41 Cr
FY 2025-26 · +20.6% YoY
- EBITDA−₹0.73 Cr
Margin -178.1%
- Net Profit−₹0.75 Cr
FY 2025-26 · +12.8% YoY
- P/E (TTM)15.4x
P/B 1.2x
- Debt / Equity0.39
Interest cover 0.0x
Associated legal entities of Ortin Laboratories
Ortin Laboratories is associated with 2 registered companies on The Company Check; the primary company is Ortin Global Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ortin Global Limited Listed CIN L68200TG1986PLC006885 | Active | 27 Oct 1986 | Hyderabad, Telangana | ₹0.4 Cr | 11 | 9 | View details |
| Vineet Chem Trade Private Limited CIN U24100TG2015PTC098656 | Active | 27 Apr 2015 | Hyderabad, Telangana | ₹22.7 Cr | 2 | View details |
Products & Services of Ortin Laboratories
Ortin Laboratories offers a comprehensive portfolio of products and services, including Formulations, API, Intermediates, and Bio-technology.
Pharmaceutical formulations are developed for various medical applications.
Active pharmaceutical ingredients are produced for drug manufacturing.
Chemical intermediates are manufactured for pharmaceutical production processes.
Biotechnology solutions are offered for healthcare and research.
Board of directors of Ortin Global Limited (Ortin Laboratories)
Ortin Global Limited is the primary company behind Ortin Laboratories. The boards of the 2 registered companies of Ortin Laboratories currently have 9 directors; the longest-serving is Gaddam Venkata Ramana, appointed in 2015. 46 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gaddam Venkata Ramana DIN 00031873 | Director | 27 Apr 2015 | 11 yrs 6 mo | Vineet Chem Trade Private Limited |
| Murali Krishna Murthy Sanka DIN 00540632 | Nodal Officer | 03 Sep 2019 | 7 yrs 2 mo | Ortin Global Limited |
| Venkptarama Gaddam DIN 02696624 | Director | 15 Jun 2022 | 4 yrs 5 mo | Vineet Chem Trade Private Limited |
| Pramod Dnyandeo Waghe DIN 10506276 | Director | 13 Feb 2024 | 2 yrs 9 mo | Ortin Global Limited |
| Mounika Pammi DIN 11111376 | Director | 26 May 2025 | 1 yr 5 mo | Ortin Global Limited |
| Sarang Balbhimrao Patodekar DIN 08501875 | Director | 10 Jul 2025 | 1 yr 4 mo | Ortin Global Limited |
| Prashant Prakash Sawant DIN 11128335 | Whole-time director | 10 Jul 2025 | 1 yr 4 mo | Ortin Global Limited |
| Ajay Vishwakarma DIN 11163644 | Director | 10 Jul 2025 | 1 yr 4 mo | Ortin Global Limited |
| Prakruti Prashant Sawant DIN 11162997 | Whole-Time Director | 10 Jul 2025 | 1 yr 4 mo | Ortin Global Limited |
People of Ortin Laboratories
1 people are tracked at Ortin Laboratories (1 in leadership).
| Name | Role | Group |
|---|---|---|
| CEO & Managing Director | Leadership |
Complete people profiles for Ortin Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ortin Laboratories
Ortin Laboratories is a publicly listed company on the NSE with ticker symbol ORTINGLOBE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Mar 2021
- Listed onNSE: ORTINGLOBE
- Listed entityOrtin Global Ltd
- Exchange sectorHealth technology
- ISININE749B01020
- Share price₹15.19 (-0.59% on the day) · 2026-10-14
- Market capitalisation₹12.1 Cr
- EPS (diluted, trailing year)₹-1.11
- Volume (last session)1,000
Financials of Ortin Laboratories
Exchange-reported figures of Ortin Global Limited, the listed company behind Ortin Laboratories (NSE: ORTINGLOBE).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.41 | 0.34 | 2.11 | 6.02 | 8.23 | 8.17 | 197 |
| Revenue growth | +20.6% | -83.9% | -65.0% | -26.9% | +0.7% | -95.9% | - |
| EBITDA | (0.73) | (0.88) | (6.54) | 0.50 | 0.36 | 1.25 | 5.69 |
| EBITDA margin | -178.1% | -258.8% | -310.0% | +8.3% | +4.4% | +15.3% | +2.9% |
| Profit before tax | (0.73) | (0.83) | (7.08) | (0.11) | (0.55) | 0.14 | 0.71 |
| Net profit | (0.75) | (0.86) | (6.28) | (0.07) | (0.42) | 0.95 | (0.57) |
| Net profit margin | -182.9% | -252.9% | -297.6% | -1.2% | -5.1% | +11.6% | -0.3% |
| EPS (βΉ) | (0.91) | (1.04) | (9.89) | (0.12) | (0.49) | 1.16 | (0.33) |
| Balance sheet | |||||||
| Total assets | 2.24 | 2.23 | 4.63 | 17.45 | 17.24 | 18.48 | 44.82 |
| Net worth | 1.24 | 1.98 | 2.82 | 10.86 | 10.96 | 11.35 | 23.82 |
| Total debt | 1.01 | 0.25 | 1.80 | 6.45 | 6.14 | 6.94 | 19.57 |
| Cash & bank | 0.61 | 0.37 | 2.34 | 0.26 | 0.60 | 0.18 | 2.50 |
| Net working capital | 1.43 | 1.78 | 4.31 | 3.04 | 2.56 | 3.73 | 23.25 |
| Cash flow | |||||||
| Cash from operations | (0.56) | (0.41) | (4.79) | (0.25) | 2.15 | 18.03 | 3.30 |
| Cash from investing | 0.04 | 0.00 | 12.00 | 0.01 | (0.13) | 0.07 | (3.09) |
| Cash from financing | 0.75 | 0.33 | (3.49) | 0.90 | (0.48) | (9.86) | (1.33) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.04 | 0.01 | 0.30 | 0.01 | 0.01 | 0.08 | 0.09 | 0.03 |
| Revenue growth (YoY) | +300.0% | -87.5% | +233.3% | -66.7% | -80.0% | -61.9% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.31 | 0.35 | 0.32 | 0.06 | 0.52 | 0.24 | 0.25 | 0.17 |
| EBITDA | (0.27) | (0.34) | (0.02) | (0.05) | (0.51) | (0.16) | (0.16) | (0.14) |
| EBITDA margin | -900.0% | -3400.0% | -66.7% | -500.0% | -5100.0% | -400.0% | -320.0% | -466.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) |
| Profit before tax | (0.27) | (0.34) | (0.02) | (0.05) | (0.51) | (0.16) | (0.16) | (0.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.04 | 0.01 | 0.30 | 0.01 | 0.01 | 0.08 | 0.09 | 0.03 |
| Revenue growth (YoY) | +300.0% | -87.5% | +233.3% | -66.7% | -80.0% | -61.9% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.31 | 0.35 | 0.32 | 0.06 | 0.52 | 0.24 | 0.25 | 0.17 |
| EBITDA | (0.27) | (0.34) | (0.02) | (0.05) | (0.51) | (0.16) | (0.16) | (0.14) |
| EBITDA margin | -900.0% | -3400.0% | -66.7% | -500.0% | -5100.0% | -400.0% | -320.0% | -466.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) |
| Profit before tax | (0.27) | (0.34) | (0.02) | (0.05) | (0.51) | (0.16) | (0.16) | (0.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.41 | 0.34 | 2.11 | 6.02 | 8.23 | 8.17 | 197 |
| Revenue growth | +20.6% | -83.9% | -65.0% | -26.9% | +0.7% | -95.9% | - |
| Other income | 0.00 | 0.06 | 0.17 | 0.04 | 0.19 | 0.05 | 0.19 |
| Total expenses | 1.14 | 1.22 | 8.65 | 5.52 | 7.87 | 6.92 | 192 |
| Employee cost | 0.00 | 0.09 | 0.49 | 0.68 | 0.74 | 0.85 | 4.72 |
| EBITDA | (0.73) | (0.88) | (6.54) | 0.50 | 0.36 | 1.25 | 5.69 |
| EBITDA margin | -178.1% | -258.8% | -310.0% | +8.3% | +4.4% | +15.3% | +2.9% |
| Depreciation | 0.00 | 0.01 | 0.23 | 0.25 | 0.29 | 0.29 | 1.96 |
| Interest | 0.00 | 0.00 | 0.48 | 0.40 | 0.81 | 0.87 | 3.21 |
| Profit before tax | (0.73) | (0.83) | (7.08) | (0.11) | (0.55) | 0.14 | 0.71 |
| Tax | 0.02 | 0.01 | 0.96 | (0.02) | (0.13) | (0.81) | 1.29 |
| Net profit | (0.75) | (0.86) | (6.28) | (0.07) | (0.42) | 0.95 | (0.57) |
| Net profit margin | -182.9% | -252.9% | -297.6% | -1.2% | -5.1% | +11.6% | -0.3% |
| EPS (βΉ) | (0.91) | (1.04) | (9.89) | (0.12) | (0.49) | 1.16 | (0.33) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 | 16.94 |
| Reserves & surplus | (6.89) | (6.15) | (5.31) | 2.73 | 2.83 | 3.22 | 6.88 |
| Shareholders' funds (net worth) | 1.24 | 1.98 | 2.82 | 10.86 | 10.96 | 11.35 | 23.82 |
| Secured loans | 0.00 | 0.00 | 0.00 | 3.49 | 3.48 | 5.91 | 2.71 |
| Unsecured loans | 1.01 | 0.25 | 1.80 | 2.96 | 2.66 | 1.03 | 16.86 |
| Total debt | 1.01 | 0.25 | 1.80 | 6.45 | 6.14 | 6.94 | 19.57 |
| Total liabilities | 2.24 | 2.23 | 4.63 | 17.45 | 17.24 | 18.48 | 44.82 |
| Assets | |||||||
| Gross block | 0.01 | 0.00 | 0.21 | 18.78 | 19.04 | 18.91 | 29.44 |
| Net block | 0.01 | 0.00 | 0.01 | 13.96 | 14.21 | 14.37 | 22.45 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.43 | 0.43 | 0.43 | 0.43 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 |
| Inventories | 0.00 | 0.02 | 0.05 | 2.60 | 1.74 | 1.83 | 49.90 |
| Sundry debtors | 0.20 | 0.26 | 1.77 | 3.42 | 3.24 | 3.91 | 37.15 |
| Cash & bank balances | 0.61 | 0.37 | 2.34 | 0.26 | 0.60 | 0.18 | 2.50 |
| Loans & advances | 3.03 | 2.68 | 2.19 | 0.26 | 0.18 | 0.20 | 2.86 |
| Total current assets | 3.84 | 3.33 | 6.35 | 6.54 | 5.76 | 6.12 | 92.41 |
| Total current liabilities | 2.41 | 1.55 | 2.04 | 3.50 | 3.20 | 2.39 | 69.16 |
| Net working capital | 1.43 | 1.78 | 4.31 | 3.04 | 2.56 | 3.73 | 23.25 |
| Total assets | 2.24 | 2.23 | 4.63 | 17.45 | 17.24 | 18.48 | 44.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.37 | 0.46 | (3.26) | (3.92) | (5.47) | (13.72) | (12.60) |
| Net cash from operating activities | (0.56) | (0.41) | (4.79) | (0.25) | 2.15 | 18.03 | 3.30 |
| Net cash from investing activities | 0.04 | 0.00 | 12.00 | 0.01 | (0.13) | 0.07 | (3.09) |
| Net cash from financing activities | 0.75 | 0.33 | (3.49) | 0.90 | (0.48) | (9.86) | (1.33) |
| Net change in cash | 0.23 | (0.09) | 3.72 | 0.66 | 1.55 | 8.25 | (1.12) |
| Closing cash | 0.61 | 0.37 | 2.34 | 0.26 | 0.60 | 0.18 | 2.50 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +20.6% | -83.9% | -65.0% | -26.9% | +0.7% | -95.9% | - |
| EBITDA growth | +17.1% | +86.5% | -1408.0% | +38.9% | -71.2% | -78.0% | - |
| PBT growth | +13.3% | +88.3% | -6336.4% | +80.0% | - | -80.3% | -61.4% |
| Net income growth | +12.8% | +86.3% | -8871.4% | +83.3% | -144.2% | +266.7% | - |
| Revenue CAGR (3Y) | -74.5% | -65.4% | -36.3% | -68.8% | -63.4% | -53.2% | +47.2% |
| EBITDA CAGR (3Y) | - | - | - | -55.5% | -62.2% | -38.6% | +1.5% |
| Profitability & leverage | |||||||
| Net income margin | -740.0% | -247.1% | -381.0% | -1.5% | -5.1% | +11.6% | -0.3% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | +1.8% | +1.6% | +3.2% | +8.7% |
| Return on net worth | 0.0% | 0.0% | 0.0% | -0.6% | -3.6% | +5.4% | -2.3% |
| Debt / equity | 0.39 | 0.43 | 0.60 | 0.58 | 0.59 | 0.75 | 0.80 |
| Long-term debt / equity | 0.39 | 0.43 | 0.35 | -15,854.61 | -15,506.46 | 0.18 | 0.20 |
| Interest cover | 0.00 | 0.00 | -7.09 | 160.00 | 1,157.14 | 90.63 | 86.06 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 20.00 | 3.24 | 0.22 | 0.32 | 0.43 | 0.34 | 7.08 |
| Inventory turnover | 10.00 | 9.71 | 1.59 | 2.77 | 4.61 | 0.32 | 4.55 |
| Debtors turnover | 0.43 | 0.33 | 0.81 | 1.81 | 2.30 | 0.40 | 5.27 |
| EPS (βΉ) | (0.91) | (1.04) | (9.89) | (0.12) | (0.49) | 1.16 | (0.33) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 1.52 | 2.43 | 3.47 | 13.36 | 13.47 | 13.97 | 14.06 |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Ortin Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ortin Laboratories
Complete news archive for Ortin Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ortin Laboratories
Ortin Laboratories was founded in 1986.
Ortin Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Murali Krishna Murthy Sanka is the CEO of Ortin Laboratories, as recorded in our data.
The primary company behind Ortin Laboratories, Ortin Global Limited, reported revenue of βΉ41 Lakh for FY 2026, up 21% year on year.
Ortin Laboratories Limited is involved in the development and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and chemical intermediates. The company is also active in biotechnology solutions and merchant export trading. Operations are focused on the healthcare sector, providing products for medical and research applications. Additionally, export and import business opportunities are pursued to expand global presence. The company is based in Hyderabad, India, and serves various clients worldwide.
Ortin Laboratories offers Formulations, API, Intermediates, and Bio-technology.
Yes, Ortin Laboratories is publicly traded on NSE under the ticker symbol ORTINGLOBE.
Ortin Laboratories is associated with 2 legal entities: Ortin Global Limited, Vineet Chem Trade Private Limited.
The legal entities of Ortin Laboratories currently have 11 directors, including Gaddam Venkata Ramana, Venkptarama Gaddam, Sarang Balbhimrao Patodekar and others.
